Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Adenocarcinoma Resectable Clear all
Completed Phase 1 Interventional

DC Vaccine in Pancreatic Cancer

NCT03592888
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
mDC3/8-KRAS Vaccine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

NCT00243854
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Tarceva
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 4, 2026, 2:37 AM EDT
Recruiting Phase 1 Interventional

CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035
View directory record Official record
Conditions
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions
CT-95
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

NCT00313560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

NCT05262855
View directory record Official record
Conditions
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Interventions
[68Ga]FAPI-46
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 4, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

NCT05132504
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Pembrolizumab, Folfirinox
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

NCT03161379
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine, Stereotactic Body Radiation (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 4, 2026, 2:37 AM EDT
Terminated Not applicable Interventional

Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation)

NCT02838966
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nestle IMPACT Advanced Recovery, Nestle Boost High Protein Drink
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 4, 2026, 2:37 AM EDT
Terminated Early Phase 1 Interventional

Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

NCT01962909
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
PTP-01
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2016 · Synced Oct 4, 2026, 2:37 AM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT04130399
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
Radiation · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 4, 2026, 2:37 AM EDT
Completed No phase listed Observational

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

NCT02685631
View directory record Official record
Conditions
Localized Non-Resectable Adult Liver Carcinoma
Interventions
Yttrium-90 Resin Microspheres
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer

NCT00002689
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dexamethasone, fluorouracil, brachytherapy, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
Center for Molecular Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
2
States / cities
Atlanta, Georgia • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 4, 2026, 2:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

NCT03483038
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Liposomal Irinotecan, FOLFOX regimen
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Gainesville, Florida • Orlando, Florida • Tallahassee, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 4, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

NCT05241249
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Bethanechol, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 4, 2026, 2:37 AM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03908333
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions
Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 4, 2026, 2:37 AM EDT
Recruiting Phase 3 Interventional

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions
daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

NCT03318497
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 4, 2026, 2:37 AM EDT
Not listed Phase 2 Interventional

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT01676259
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
siG12D-LODER, Gemcitabine+nab-Paclitaxel, Folfirinox
Drug
Lead sponsor
Silenseed Ltd
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 4, 2026, 2:37 AM EDT
Active, not recruiting Phase 2 Interventional

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

NCT05604560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Tislelizumab, SX-682
Drug
Lead sponsor
Lei Zheng
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 4, 2026, 2:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

NCT03368963
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

NCT00557492
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
Drug · Radiation
Lead sponsor
Amer Zureikat
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Neoadjuvant FOLFIRINOX

NCT02178709
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma
Interventions
FOLFIRINOX
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 4, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body

NCT02208024
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 4, 2026, 2:37 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 4, 2026, 2:37 AM EDT